Hallmarks and novel insights for gastrointestinal stromal tumors: A bibliometric analysis

被引:3
|
作者
Li, Chen [1 ]
Wang, Quan [2 ]
Jiang, Ke-Wei [1 ,3 ]
Ye, Ying-Jiang [1 ]
机构
[1] Peking Univ Peoples Hosp, Dept Gastroenterol Surg, Lab Surg Oncol, Beijing Key Lab Colorectal Canc Diag & Treatment R, Beijing 100044, Peoples R China
[2] Air Force Mil Med Univ, Xijing Hosp, Ambulatory Surg Ctr, Xian 710032, Peoples R China
[3] Peking Univ Peoples Hosp, Dept Gastroenterol Surg, Lab Surg Oncol, Beijing Key Lab Colorectal Canc Diag & Treatment R, 11 Xizhimen South St, Beijing 100044, Peoples R China
来源
EJSO | 2023年 / 49卷 / 12期
关键词
Gastrointestinal stromal tumors; Bibliometric analysis; Trends; FINE-NEEDLE-ASPIRATION; INTERSTITIAL-CELLS; C-KIT; IMATINIB RESISTANCE; MUTATIONS; GIST; DIAGNOSIS; INHIBITION; PATHOLOGY; MESYLATE;
D O I
10.1016/j.ejso.2023.107079
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Due to the increasing recognition of gastrointestinal stromal tumor (GIST), novel insights have appeared in both preclinical and clinical research and begun to reshape the field. This study aims to map the research landscape through bibliometric analysis and provide a brief overview for the future of the GIST field. Methods: We searched the Web of Science Core Collection without publication data restrictions for GISTs and performed a bibliometric analysis with CiteSpace and VOSviewer software. Results: In sum, 5,911 of 13,776 records were included, and these studies were published in 948 journals and written by 24,965 authors from 4,633 institutions in 100 countries. Referring to published reviews and biblio-metric analysis, we classified the future trends in four groups. In epidemiological study, precise incidence and clinicopathological features in different regions and races might become potential hotspots. Novel therapy, such as drugs, modified strategies, radioligand therapy, was persistent hotspots in GIST fields, and ctDNA-guided diagnosis, monitoring, and treatment might meet future clinical needs. The debate over serosa surgery vs. mucosa surgery will remain active for a long time in GIST surgery, and function reserve surgery, biology-based surgery will play an important role in future. Moreover, rare GIST type, like NF-1-associated GIST, Carney tri-ads and SDH mutant GIST, need more studies in pathogenesis and genetic mutation to provide appropriate treatment for this orphan GIST patients.Conclusions: Potential hotspots in future GIST trends might involve epidemiology, agents, resection therapy and rare type GIST, moreover, researchers could pay more attention in these four fields.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Gastrointestinal stromal tumors
    Ridolfini, Marco Pericoli
    Cassano, Alessandra
    Ricci, Riccardo
    Rotondi, Fabio
    Berardi, Stefano
    Cusumano, Giacomo
    Pacelli, Fabio
    Doglietto, Giovanni Battista
    ANNALI ITALIANI DI CHIRURGIA, 2011, 82 (02) : 97 - 109
  • [2] Novel perspectives on gastrointestinal stromal tumors (GISTs)
    Manolescu, Bogdan Stelian Mastalier
    Popp, Cristiana Gabriela
    Popescu, Valentin
    Andras, Dan
    Zurac, Sabina Andrada
    Berceanu, Costin
    Petca, Aida Tincuta
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2017, 58 (02) : 339 - 350
  • [3] Gastrointestinal stromal tumors
    Agaimy, A.
    Schneider-Stock, R.
    PATHOLOGE, 2010, 31 (02): : 115 - 122
  • [4] Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors
    Serrano, Cesar
    George, Suzanne
    Valverde, Claudia
    Olivares, David
    Garcia-Valverde, Alfonso
    Suarez, Cristina
    Morales-Barrera, Rafael
    Carles, Joan
    TARGETED ONCOLOGY, 2017, 12 (03) : 277 - 288
  • [5] Gastrointestinal stromal tumors. Diagnosis and treatment
    Acin-Gandara, Debora
    Pereira-Perez, Fernando
    Castano-Pascual, Angel
    Duran-Poveda, Manuel
    Antequera-Perez, Alfonso
    Miliani-Molina, Carlos
    CIRUGIA Y CIRUJANOS, 2012, 80 (01): : 42 - 49
  • [6] Establishment and characterization of novel cell lines and xenografts from patients with gastrointestinal stromal tumors
    Fukuda, Kazumasa
    Saikawa, Yoshiro
    Sako, Hiroyuki
    Yoshimura, Yumi
    Takahashi, Tsunehiro
    Wada, Norihito
    Kawakubo, Hirohumi
    Takeuchi, Hiroya
    Ohmori, Tai
    Kitagawa, Yuko
    ONCOLOGY REPORTS, 2013, 30 (01) : 71 - 78
  • [7] Incidence and Survival Outcomes of Gastrointestinal Stromal Tumors
    Alvarez, Christian S.
    Piazuelo, M. Blanca
    Fleitas-Kanonnikoff, Tania
    Ruhl, Jennifer
    Perez-Fidalgo, J. Alejandro
    Camargo, M. Constanza
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [8] Update on imatinib for gastrointestinal stromal tumors: duration of treatment
    Linch, Mark
    Claus, Jeroen
    Benson, Charlotte
    ONCOTARGETS AND THERAPY, 2013, 6 : 1011 - 1023
  • [9] Extra-gastrointestinal Stromal Tumors (EGISTs): Review of Four Cases with Immunohistoehemical Analysis
    Bernardo Fonseca, Ismael
    Cesar Guerini, Julio
    Strelzik, Ines
    Ghirardi, Graciela
    Gramatica, Luis
    Esteban Avila, Rodolfo
    Santos Spitale, Luis
    INTERNATIONAL JOURNAL OF MORPHOLOGY, 2010, 28 (04): : 991 - 998
  • [10] Gastrointestinal Stromal Tumors: Current Management
    Pisters, Peter W. T.
    Patel, Shreyaskumar R.
    JOURNAL OF SURGICAL ONCOLOGY, 2010, 102 (05) : 530 - 538